Duafalia F. Dudimah

发表

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.

D. Longo, T. Sayers, A. Brooks, 2015, Cancer research.

Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk

D. Carbone, M. Dikov, R. Uzhachenko, 2015, Oncotarget.

Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy.

Jason V. Evans, D. Carbone, A. Biktasova, 2015, Cancer research.

Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function

A. Richmond, R. Uzhachenko, A. Shanker, 2016, Oncotarget.

Modulatory effects of bortezomib on host immune cell functions.

T. Sayers, A. Shanker, S. Pellom, 2015, Immunotherapy.

Abstract 4161: Bortezomib enhances expression of effector molecules in antitumor CD8+ T lymphocytes by modulating Notch-NF-kB-miR-155 crosstalk

R. Uzhachenko, A. Shanker, S. Pellom, 2016 .

Cancer therapy by resuscitating Notch immune surveillance

D. Carbone, M. Dikov, R. Uzhachenko, 2014, Journal of Immunotherapy for Cancer.

Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy.

Jason V. Evans, D. Carbone, A. Biktasova, 2015, Cancer research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.